Fluorine in psychedelic phenethylamines

The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans

(2011) C M Hysek et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Irving Page Lecture: 5-HT2A serotonin receptor biology: Interacting proteins, kinases and paradoxical regulation

(2011) Bryan L. Roth   NEUROPHARMACOLOGY

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

(2010) Charles S. Grob et al.   ARCHIVES OF GENERAL PSYCHIATRY

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

(2010) Franz X. Vollenweider et al.   NATURE REVIEWS NEUROSCIENCE

Psychedelics and the Human Receptorome

(2010) Thomas S. Ray   PLoS One

Hallucinogens as Medicine

(2010) Roland R. Griffiths et al.   SCIENTIFIC AMERICAN

Molecular Dynamics Simulation of the Heterodimeric mGluR2/5HT2AComplex. An Atomistic Resolution Study of a Potential New Target in Psychiatric Conditions

(2009) Agostino Bruno et al.   Journal of Chemical Information and Modeling

Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview

(2009) João Paulo Capela et al.   MOLECULAR NEUROBIOLOGY

The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands

(2008) Matthew A. Parker et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The Many Roles for Fluorine in Medicinal Chemistry

(2008) William K. Hagmann   JOURNAL OF MEDICINAL CHEMISTRY

Comparative Molecular Field Analysis Using Selectivity Fields Reveals Residues in the Third Transmembrane Helix of the Serotonin Transporter Associated with Substrate and Antagonist Recognition

(2008) C. C. Walline et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS